Premium
Redox‐Based Assay for Assessment of Biological Impact of Plasma Treatment
Author(s) -
Wende Kristian,
Reuter Stephan,
von Woedtke Thomas,
Weltmann KlausDieter,
Masur Kai
Publication year - 2014
Publication title -
plasma processes and polymers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.644
H-Index - 74
eISSN - 1612-8869
pISSN - 1612-8850
DOI - 10.1002/ppap.201300172
Subject(s) - hacat , plasma , human plasma , jurkat cells , flexibility (engineering) , chemistry , materials science , chromatography , in vitro , mathematics , immunology , biochemistry , physics , biology , statistics , immune system , quantum mechanics , t cell
Commonly, non‐thermal plasma sources for medical applications are compared by the quantity of reactive components they produce. Here, a different perspective is chosen: A cell viability assay, which can act as standard procedure to compare plasma sources by the biological effectiveness is proposed. This assay can easily be performed with a minimum of technical equipment. It allows the estimation of the biological impact of a plasma source. For maximum flexibility, an indirect plasma treatment procedure is combined with a dilution method. The applicability of the assay is demonstrated by assessing the impact of different non‐thermal plasma sources (kINPen & kINPen med, µAPPJ, water discharge, DBE) and the use of a series of human cell lines and their response to a kINPen treatment (HaCaT, MV3, Jurkat, THP‐1, MRC‐5).